MiRNA-101 Targets TGF-βR1 to Retard the Progression of Oral Squamous Cell Carcinoma

Overview

Journal Oncol Res

Specialty Oncology

Date 2019 Dec 14

PMID 31831099

Citations 9

Authors

Yong Wang

Rui-Zhi Jia

Shu Diao

Jun He

Li Jia

Affiliations

Soon will be listed here.

Abstract

Despite the considerable knowledge on the involvement of microRNA-101 (miR-101) in the evolution of oral squamous cell carcinoma (OSCC), the underlying mechanisms remain obscure. In this study, miR-101 expression was markedly downregulated in the OSCC cell lines and tissues. Cell counting kit-8 (CCK-8), ethynyl deoxyuridine (EdU), and colony formation assays showed that miR-101 inhibited the proliferation of OSCC cells. Flow cytometry and caspase 3 activity assays indicated that miR-101 induced OSCC cell apoptosis. Transwell assays demonstrated that this miRNA also repressed OSCC cell migration and invasion. Moreover, tube formation assay showed that miR-101 abated the proangiogenesis of OSCC cells. Dual-luciferase reporter assay confirmed that miR-101 directly targeted transforming growth factor-β receptor 1 (TGF-βR1) in OSCC. Ectopic expression of TGF-βR1 counteracted the effects of miR-101 on the OSCC cell characteristics. Thus, miR-101 significantly abolished the proliferation, motility, and proangiogenesis of OSCC cells and induced their apoptosis by targeting TGF-βR1. These results imply the potential application of miR-101 in OSCC treatment.

Citing Articles

Investigating the miRNA-mRNA interactome of human trabecular meshwork cells treated with TGF-β1 provides insights into the pathogenesis of pseudoexfoliation glaucoma.

Roodnat A, Doyle C, Callaghan B, Lester K, Henry M, Sheridan C PLoS One. 2025; 20(1):e0318125.

PMID: 39883689 PMC: 11781692. DOI: 10.1371/journal.pone.0318125.

XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC.

Han Y, Peng Y, Xiong H, Zeng L, Zhang T, Xia K Cancer Med. 2024; 13(16):e70076.

PMID: 39177040 PMC: 11342079. DOI: 10.1002/cam4.70076.

Relevance of micro-RNAs and their targets as a diagnostic and prognostic marker in oral squamous cell carcinoma.

Thomas P, Preethi K, Selvakumar S, Ramani P, Sekar D J Oral Maxillofac Pathol. 2023; 27(2):364-373.

PMID: 37854932 PMC: 10581285. DOI: 10.4103/jomfp.jomfp_349_22.

Eslami M, Khazeni S, Mohammadi Khanaghah X, Asadi M, Ansari M, Garjan J Cancer Cell Int. 2023; 23(1):182.

PMID: 37635248 PMC: 10463971. DOI: 10.1186/s12935-023-03022-5.

Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape.

Gu J, Chen J, Xiang S, Zhou X, Li J J Adv Res. 2023; 54:147-179.

PMID: 36736694 PMC: 10703639. DOI: 10.1016/j.jare.2023.01.011.

References

Hui Y, Li Y, Jing Y, Feng J, Ding Y . miRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7. Am J Transl Res. 2016; 8(11):4902-4911. PMC: 5126332. View

Karatas O, Oner M, Abay A, Diyapoglu A . MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications. Oral Oncol. 2017; 67:124-130. DOI: 10.1016/j.oraloncology.2017.02.015. View

Wang X, Abraham S, McKenzie J, Jeffs N, Swire M, Tripathi V . LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature. 2013; 499(7458):306-11. PMC: 3836402. DOI: 10.1038/nature12345. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Zhao X, Wang K, Liao Y, Zeng Q, Li Y, Hu F . MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFβRI on cardiac fibroblasts. Cell Physiol Biochem. 2015; 35(1):213-26. DOI: 10.1159/000369689. View

Wu B, Lei D, Wang L, Yang X, Jia S, Yang Z . MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. Am J Cancer Res. 2016; 6(6):1396-407. PMC: 4937741. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Jensen D, Dabelsteen E, Specht L, Fiehn A, Therkildsen M, Jonson L . Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma. J Pathol. 2015; 236(4):505-16. DOI: 10.1002/path.4550. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

10.

Ferrari G, Cook B, Terushkin V, Pintucci G, Mignatti P . Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol. 2009; 219(2):449-58. PMC: 2749291. DOI: 10.1002/jcp.21706. View

11.

Miao L, Wang L, Yuan H, Hang D, Zhu L, Du J . MicroRNA-101 polymorphisms and risk of head and neck squamous cell carcinoma in a Chinese population. Tumour Biol. 2015; 37(3):4169-74. DOI: 10.1007/s13277-015-4249-6. View

12.

Cao K, Li J, Zhao Y, Wang Q, Zeng Q, He S . miR-101 Inhibiting Cell Proliferation, Migration and Invasion in Hepatocellular Carcinoma through Downregulating Girdin. Mol Cells. 2016; 39(2):96-102. PMC: 4757808. DOI: 10.14348/molcells.2016.2161. View

13.

Guan H, Dai Z, Ma Y, Wang Z, Liu X, Wang X . MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer. Int J Mol Med. 2016; 37(6):1643-51. DOI: 10.3892/ijmm.2016.2557. View

14.

Ketabat F, Pundir M, Mohabatpour F, Lobanova L, Koutsopoulos S, Hadjiiski L . Controlled Drug Delivery Systems for Oral Cancer Treatment-Current Status and Future Perspectives. Pharmaceutics. 2019; 11(7). PMC: 6680655. DOI: 10.3390/pharmaceutics11070302. View

15.

Mangalhara K, Manvati S, Saini S, Ponnusamy K, Agarwal G, Abraham S . ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett. 2017; 391:59-73. DOI: 10.1016/j.canlet.2017.01.016. View

16.

Cheng C, Shiah S, Huang C, Hsiao J, Chang J . Up-regulation of miR-455-5p by the TGF-β-SMAD signalling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. J Pathol. 2016; 240(1):38-49. DOI: 10.1002/path.4752. View

17.

Sun H, Miao C, Liu W, Qiao X, Yang W, Li L . TGF-β1/TβRII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages. Biochem Biophys Res Commun. 2018; 497(2):583-590. DOI: 10.1016/j.bbrc.2018.02.104. View

18.

Wang C, Deng F, Li H, Wang D, Zhang W, Ding L . MiR-101: a potential therapeutic target of cancers. Am J Transl Res. 2019; 10(11):3310-3321. PMC: 6291716. View

19.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

20.

Xiong W, Han N, Wu N, Zhao K, Han C, Wang H . Interplay between long noncoding RNA ZEB1-AS1 and miR-101/ZEB1 axis regulates proliferation and migration of colorectal cancer cells. Am J Transl Res. 2018; 10(2):605-617. PMC: 5835826. View